Merck & Co., Inc. - Form 8-K (Q1 2026 Earnings Release)

Merck & Co., Inc. reported its first-quarter 2026 financial results on April 30, 2026. The company announced worldwide sales of $16.3 billion, a 5% increase year-over-year (3% excluding foreign exchange). Key drivers included strong performance in oncology, with KEYTRUDA/KEYTRUDA QLEX sales reaching $8.0 billion (12% growth), and significant growth in WINREVAIR (88% growth) and Animal Health (13% growth). However, the company reported a GAAP loss per share of $1.72 and a non-GAAP loss per share of $1.28, both impacted by a $3.62 per share charge for the acquisition of Cidara. Merck also highlighted several regulatory approvals and clinical milestones, including FDA approval for IDVYNSO for HIV-1 treatment and advancements in its oncology pipeline. The company updated its full-year 2026 financial outlook, narrowing and raising the midpoint of its worldwide sales range to $65.8 billion - $67.0 billion and its non-GAAP EPS range to $5.04 - $5.16. The outlook does not include the proposed acquisition of Terns Pharmaceuticals, expected to close in May and result in a significant one-time charge.